ClinicalTrials.gg
RecruitingNCT07252531BRIOLIFEUpdated Jun 22, 2026

European Study of the BrioVAD Heart Pump for Advanced Heart Failure

An interventional study of LVAD implantation in Refractory Heart Failure and Cardiovascular Diseases (CVD), sponsored by BrioHealth BV. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by BrioHealth BV · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Heart Failure with a site in Netherlands — 57 open to participants now, 80 under way, 13 of them phase 3. Heart Failure · Netherlands.

Planned enrollment
174th of 234
60 · median 284
Started
2026
with 17 others
No phase
105 of 313
19 open now
Primary completion
2027-07
later than 38 of 79 live
Registered
295th of 313
by date

Among the 313 studies in Heart Failure with a site in Netherlands, this one is the 174th largest by planned enrollment of the 234 interventional ones that give a count, is one of 18 that started in 2026, is one of 105 with no phase, reaches primary completion later than 38 of the 79 other live ones, and was the 295th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

57 of the 313 studies in Heart Failure with a site in Netherlands are open now. Recruiting first, the newest first:

51 more — sign in →

All 57 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Heart Failure with a site in Netherlands, or all of them as a file.
02

Study summary

This clinical investigation evaluates the safety and clinical performance of the BrioVAD Left Ventricular Assist System in patients with advanced, refractory left ventricular heart failure who require mechanical circulatory support.

Read the detailed description

This clinical investigation is conducted to assess the clinical performance and safety of the BrioVAD Left Ventricular Assist System (BrioVAD System) when used for mechanical circulatory support in patients with advanced, refractory left ventricular heart failure.

The BrioVAD System is a fully magnetically levitated, centrifugal-flow left ventricular assist device (LVAD) intended to provide short-term and long-term mechanical circulatory support (MCS) in patients with advanced, refractory heart failure who remain symptomatic despite optimal medical and device therapy. The BrioVAD System is intended for use both inside and outside the hospital environment.

This investigation is designed as a prospective, multi-centre, single-arm, non-inferiority clinical investigation. The performance of the BrioVAD System will be evaluated against a pre-defined Objective Performance Goal (OPG) based on contemporary LVAD clinical outcomes.

The primary objective is to demonstrate that the BrioVAD System provides non-inferior clinical benefit, as measured by survival free from device replacement/removal due to device malfunction at 6 months post-implant, compared with the OPG.

03

Conditions studied

  • Refractory Heart Failure
  • Cardiovascular Diseases (CVD)

Keywords

  • BrioVAD System
  • Left Ventricular Assist Device
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is ≥ 18 years of age.
  2. Patient has a body surface area (BSA) ≥ 1.2 m2.
  3. Patient is classified as Class IV with advanced heart failure to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.
  4. Patient has a (LVEF) ≤ 25% or LVEF \< 30% on inotropes or intra-aortic balloon pump (IABP).
  5. Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters/min/m2, while not on inotropes, and also meets one of the following criteria:

    1. Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or
    2. Has advanced heart failure for at least 14 days and is dependent on an IABP for at least seven days.
  6. Patient has provided voluntary and .
  7. Females of childbearing age agree to use adequate and have a negative pregnancy test.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis/senile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and/or pericardial disease.
  2. Patient had a myocardial infarction within seven days before study enrollment.
  3. Patient had cardiothoracic surgery within 30 days before implant.
  4. Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.
  5. Patient has to warfarin anticoagulation.
  6. Patient has known hypo- or hypercoagulable state [e.g., disseminated intravascular coagulation (DIC)], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.
  7. Patient is on durable MCS (e.g., LVAD or RVAD).
  8. Planned need for durable or temporary RVAD support concomitant with LVAD implant.
  9. Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an IABP.
  10. Patient is on any form of pre-implant temporary MCS with a serum lactate dehydrogenase greater than 2.5 times the or with plasma free > 40 g/dL.
  11. Patient has a history of organ transplantation.
  12. Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.
  13. Patient has a count \< 50 k/µl.
  14. Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter.
  15. Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.
  16. Patient has an uncontrolled systemic infection.
  17. Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin >1000 ug/L.
  18. Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:

    1. Total > 3.0 mg/dL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without confirmation.
    2. (INR) ≥ 2.0 or PTT > 2.5 times control that is not related to anticoagulation therapy.
    3. (GFR) \< 30 mL/ min/1.73 m2 or need for renal replacement therapy.
    4. Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.
    5. Severe (COPD) or restrictive lung disease requiring home oxygen or an /FVC \< 0.7 and FEV1 \< 40% predicted.
    6. Mechanical ventilation for more than three days present at the time of study enrollment.
    7. Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.
    8. History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.
    9. Symptomatic cerebrovascular disease and/or uncorrected carotid stenosis > 80%.
    10. Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.
    11. Pre-albumin \< 15 mg/dL and/or albumin \< 2.5 g/dL.
  19. Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.
  20. Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and/or insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.
  21. Patient is participating in an interventional clinical trial that may impact or confound the results of the BrioVAD Trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Device: LVAD implantation

Interventions

  • DeviceLVAD implantation

    Implantation of an LVAD in the chest

06

What researchers measure

Primary outcomes

  1. Survival rate at 6 months

    Time frame: From enrollment to 6 months on device support

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2027, 13 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 13 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 26, 2025
StartActual
Jun 1, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jan 31, 2029
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07252531
Lead sponsor
BrioHealth BV
Collaborators
Meditrial SrL
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Jun 1, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Jun 22, 2026

Study contacts

Piet Jansen, MD, PhD
Contact
piet.jansen@briohealthtech.com
+31644046783
Helmine Verhoeven
Contact
helmine.verhoeven@briohealthtech.com
+31638620467

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion